Literature DB >> 35306242

Post COVID-19 infection neuromyelitis optica spectrum disorder (NMOSD): A case report-based systematic review.

Omid Mirmosayyeb1, Elham Moases Ghaffary2, Sara Bagherieh2, Mahdi Barzegar1, Mohammad Sadegh Dehghan2, Vahid Shaygannejad3.   

Abstract

BACKGROUND: One of the rare neuroinflammatory disorders is Neuromyelitis optica spectrum disorder (NMOSD) which involves the central nervous system (CNS), and develops by various etiologies. There is evident that viral infections could cause neurological disorders. In this regard, novel coronavirus (COVID-19) triggers NMOSD, based on reports. We performed this systematic review to evaluate NMOSD patients following COVID-19 infection.
METHODS: We collected 345 studies from PubMed (Medline), Embase, Scopus, and Web of Science databases from inception to 20 October 2021, and our inclusion criteria were English case reports/case series. Other types of Coronaviridae virus studies, review articles, articles written in any language other than English were excluded as well.
RESULTS: 11 case reports were selected from 345 studies and data was extracted according to inclusion criteria. In all cases, NMOSD was reported following COVID-19 infection, and various symptoms such as blurring or loss of vision, weakness, and numbness were common, and the COVID-19 infection was confirmed by different tests such as PCR test, immunoglobulin assay and chest imaging.
CONCLUSION: Review regarding case reports showed that NMOSD is conceivable following COVID-19.
Copyright © 2022. Published by Elsevier B.V.

Entities:  

Keywords:  COVID-19; Devic disease; NMOSD; Neuromyelitis optica Spectrum disorder; SARS-CoV-2

Mesh:

Year:  2022        PMID: 35306242     DOI: 10.1016/j.msard.2022.103697

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  1 in total

1.  A Case Presenting with Neuromyelitis Optica Spectrum Disorder and Infectious Polyradiculitis Following BNT162b2 Vaccination and COVID-19.

Authors:  Youngho Kim; Donghyun Heo; Moonjeong Choi; Jong-Mok Lee
Journal:  Vaccines (Basel)       Date:  2022-06-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.